Skanttr Lifescience развивает портфель API нового поколения, ориентированный на ключевые потребности глобального здравоохранения. Наши основные продукты включают Prussian Blue для лечения радиационного заражения, Aceclidine HCl для современной офтальмологии и Imeglimin HCl — инновационный препарат для лечения диабета, воздействующий на митохондриальную функцию. Параллельно мы разрабатываем ряд сложных и инновационных API в сегментах ЦНС, онкологии и специализированной терапии. Мы обеспечиваем высокое качество производства, готовность к регуляторным требованиям и надежные глобальные поставки.
Skanttr Lifescience is advancing a next-generation API portfolio focused on critical global healthcare needs. Our key offerings include Prussian Blue for nuclear radiation management, Aceclidine HCl for advanced ophthalmic therapies, and Imeglimin HCl, a novel anti-diabetic agent targeting mitochondrial bioenergetics. Alongside these, we are developing a pipeline of innovative and complex APIs across CNS, oncology, and specialty segments. Our approach integrates high-quality manufacturing, regulatory readiness, and strategic global supply capabilities to support partners in addressing emerging therapeutic challenges and ensuring patient safety worldwide.
Skanttr Lifescience is advancing a next-generation API portfolio focused on critical global healthcare needs. Our key offerings include Prussian Blue for nuclear radiation management, Aceclidine HCl for advanced ophthalmic therapies, and Imeglimin HCl, a novel anti-diabetic agent targeting mitochondrial bioenergetics. Alongside these, we are developing a pipeline of innovative and complex APIs across CNS, oncology, and specialty segments. Our approach integrates high-quality manufacturing, regulatory readiness, and strategic global supply capabilities to support partners in addressing emerging therapeutic challenges and ensuring patient safety worldwide.